SQZ, Roche expand deal to jointly develop cancer cell therapies

By Mark Zipkin | Oct 15, 2018 | 2:41 PM GMT

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy strategies.

The

Read the full 378 word article

How to gain access

Continue reading with a
two-week free trial.